(Amends number of participants in second paragraph to 550 from 590 after health ministry corrects figures)
MADRID, Aug 28 (Reuters) - Johnson & Johnson’s Janssen unit will begin Phase II trials for its COVID-19 vaccine in Spain, the Netherlands and Germany next week, Spanish health minister Salvador Illa announced on Friday, as the U.S. drugmaker expands testing for its experimental shot.
The trial will last two months and include 550 participants across the three countries, including 190 people in Spain, Illa told a news conference in Madrid.
More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 30 in human trials. There is so far no approved COVID-19 vaccine, except one authorised in Russia before large-scale trials. (Reporting by Nathan Allen and Jose Elías Rodríguez; Editing by Belén Carreño)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.